-
Product Insights
NewAllergic Asthma – Drugs In Development, 2024
Empower your strategies with our Allergic Asthma – Drugs In Development, 2024 report and make more profitable business decisions. Allergic asthma is a type of asthma triggered by exposure to allergens, substances that induce an allergic reaction in susceptible individuals. When someone with allergic asthma encounters these triggers, their immune system responds by inflaming and constricting the airways, leading to symptoms of asthma. Common allergens that can trigger asthma include pollen, dust mites, pet dander, mold, cockroach droppings, and certain foods....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avizakimab in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avizakimab in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Avizakimab in Systemic Lupus Erythematosus Drug Details:Avizakimab (BOS-161721) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SB-012 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SB-012 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SB-012 in Ulcerative ColitisDrug Details:SB-012 is under development for the treatment of ulcerative...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SB-012
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SB-012 Drug Details SB-012 is under development for the treatment of ulcerative colitis. The...
-
Product Insights
Asthma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Asthma, a chronic disease involving the airways in the lungs, may occur with symptoms that include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The Asthma pipeline drugs market research report outlays comprehensive information on the Asthma targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in...
-
Product Insights
Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic Obstructive Pulmonary Disease (COPD) symptoms include inability to completely breathe out air from the lungs leading to shortness of breath. Other symptoms include cough, fatigue, and chest pain. The COPD pipeline drugs market research report provides an analysis of the COPD drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest...
-
Product Insights
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis – Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer,...
-
Sector Analysis
Competitor Landscape: Atopic Dermatitis
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Atopic Dermatitis (AD) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher